Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves first Parkinson’s dyskinesia drug

The FDA approved Adamas Pharmaceuticals Inc’s treatment for a side effect caused by a commonly prescribed Parkinson’s drug.

Read More »

Last ‘bare county’ in U.S. to get health insurer next year

Ohio’s Department of Insurance said non-profit managed care company CareSource will sell health plans in Paulding County in 2018 – the last county in the United States that would have been without Obamacare individual coverage during the year.

Read More »

ISPOR/ISPE Announce Plans for “Summit on Real-World Evidence in Health Care Decision Making”

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Society for Pharmacoepidemiology (ISPE) announced their plans for a one-day conference focused on real-world evidence.

Read More »

Novel Gene Therapy Shows Three-Fold Improvement in Recurrence-Free Survival in High-Risk, Early-Stage Bladder Cancer Patients Where Current Gold-Standard Treatment Fails

The Society of Urologic Oncology and the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) announced that the Journal of Clinical Oncology published results from a Phase II clinical study led by the SUO-CTC demonstrating the potential effectiveness of Instiladrin (rAD-IFN/Syn3) in patients with high grade, BCG refractory or relapsed Non-Muscle Invasive Bladder Cancer.

Read More »

Job Cuts and Facility Reductions Loom Over SoCal’s ImmunoCellular

Financial concerns continue to plague ImmunoCellular Therapeutics as the company continues to look for cost-cutting measures that will provide enough resources to fund continued R&D on the company’s Stem-to-T-Cell research program.

Read More »

New data boosts case for extended use of AstraZeneca heart drug

AstraZeneca’s blood-thinner Brilinta cuts the risk of cardiovascular death by 29 percent in patients with a history of past heart attacks who keep taking it beyond the standard 12-month initial period, according to new clinical trial data.

Read More »

EU approves breast cancer drug Kisqali

Novartis AG’s Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer.

Read More »

FDA grants priority review to hemophilia drug

Swiss pharma group Roche said the U.S. Food and Drug Administration granted priority review to its emicizumab for hemophilia A with inhibitors.

Read More »

GSW Names Sonja Foster-Storch President

GSW, an INC Research/inVentiv Health company and industry leader in healthcare advertising, named Sonja Foster-Storch as President. Foster-Storch reports to Lisa Stockman, President of inVentiv Health Communications.

Read More »

Vision loss associated with cognitive decline, dementia

Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.

Read More »

Brain activity tied to blood pressure during stress

Brain scans obtained during psychological stress might someday help doctors identify people who are at higher risk for heart disease, a new study suggests.

Read More »

India’s proposed pharma marketing rules hit legal roadblock

India’s plan to bring in marketing rules to curb unethical promotional practices in the country’s drug industry faces an indefinite delay after it hit a legal roadblock, marking a setback for public health groups.

Read More »

IBM: Your Computer Can Help Scientists Study Connection Between Body Bacteria and Autoimmune Diseases

The general public’s help is being enlisted in what is believed to be the largest study of the human microbiome – the bacteria that live in and on the human body – and are believed to affect health.

Read More »

Muscle Disease Drug Development Halted

A Phase 3 study evaluating Ultragenyx Pharmaceuticals’ aceneuramic acid extended release in patients with GNE Myopathy did not achieve its primary endpoint.

Read More »

Boston’s Paratek Heads to Auction Block

Shares of Paratek rocketed upward after the antibiotics specialist posted a “for sale” sign on the doors.

Read More »

Anthem Reaches Goal Two Years Early for Health Plans to Reduce Opioids Filled at Pharmacy by 30 Percent

Anthem Inc. is committed to supporting policy changes that help reduce, prevent and deter opioid use disorder, as well as those that help consumers better access treatment. As part of that commitment, its affiliated health plans just reached the company’s collective goal of reducing prescribed opioids filled at pharmacies by 30 percent during the past five years.

Read More »

Argentum, Lilly Settle Cialis Patent Dispute

Argentum Pharmaceuticals announced that it reached a settlement and license agreement with Eli Lilly related to Argentum’s generic version of Cialis (tadalifil).

Read More »

New York Festivals Global Awards Announces 2017 Executive and Grand Juries

New York Festivals Global Awards, honoring the World’s Best Healthcare & Wellness Advertising, announced the 2017 Executive and Grand Juries.

Read More »

After solar eclipse, Americans’ eyes seem mostly none the worse

Eye doctors who had braced themselves for at least a few patients after a dazzling solar eclipse swept the United States cautiously exhaled, with some hospitals reporting zero cases of damaged vision so far.

Read More »

India grants Pfizer patent on pneumonia vaccine in blow to aid group

India granted Pfizer Inc. a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom